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Abstract
Background: Biomedical knowledge graphs have become important tools to computationally analyse the
comprehensive body of biomedical knowledge. They represent knowledge as subject-predicate-object triples, in
which the predicate indicates the relationship between subject and object. A triple can also contain provenance
information, which consists of references to the sources of the triple (e.g. scientific publications or database
entries). Knowledge graphs have been used to classify drug-disease pairs for drug efficacy screening, but existing
computational methods have often ignored predicate and provenance information. Using this information, we
aimed to develop a supervised machine learning classifier and determine the added value of predicate and
provenance information for drug efficacy screening. To ensure the biological plausibility of our method we
performed our research on the protein level, where drugs are represented by their drug target proteins, and
diseases by their disease proteins.
Results: Using random forests with repeated 10-fold cross-validation, our method achieved an area under
the ROC curve (AUC) of 78.1% and 74.3% for two reference sets. We benchmarked against a state-of-the-art
knowledge-graph technique that does not use predicate and provenance information, obtaining AUCs of 65.6% and
64.6%, respectively. Classifiers that only used predicate information performed superior to classifiers that only used
provenance information, but using both performed best.
Conclusion: We conclude that both predicate and provenance information provide added value for drug efficacy
screening.
Keywords: Predicate, Provenance, Drug efficacy screening, Machine learning, Knowledge graph, Drug repurposing,
Systems pharmacology, Computational pharmacology
Background
Knowledge graphs describe biomedical entities, such as
diseases, proteins, or drugs, and their relationships [1].
They represent knowledge by subject-predicate-object tri-
ples, in which the predicate indicates the relationship be-
tween an entity pair (subject and object) [2]. A triple can
also be enriched with provenance information, which con-
sists of references to the sources where the triple is de-
scribed. For example, the triple OPRM1-forms protein
complex with-GNAT2 is described in the Reactome data-
base [3]. Using triples, knowledge contained in a variety of
sources, ranging from scientific articles to biomedical da-
tabases, can be incorporated within knowledge graphs [4].
Knowledge graphs have been applied to multiple prob-
lems in biomedical research, such as the extraction of
disease biomarkers [5], identification of disease mecha-
nisms [6], and numerous pharmacological use cases in the
Open PHACTS project [7]. One of the most important
use cases in computational pharmacology is the predic-
tion of the health benefits of a drug over a placebo, i.e.
its efficacy [8].
Many knowledge-graph methods have already been
developed for predicting the efficacy of drugs [9–16].
Most of these methods do not use predicate or provenance
information, but use the similarity between drugs to pre-
dict their efficacy for diseases. These methods count the
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number of common entities in a graph between two drugs,
or between a drug and a disease. The underlying assump-
tion of these methods is that a high number of common
entities indicates similarity between drugs, which are there-
fore likely to be efficacious for the same diseases. They typ-
ically perform well for existing, well-characterized drugs.
However, Guney demonstrated that the performance of
similarity-based methods drops drastically when predicting
the efficacy of drugs that are new, poorly characterized, or
dissimilar to other drugs [17]. He considered the limited
insight that these methods offer into the mechanisms be-
hind the efficacy of the drugs as another drawback.
In other work, Guney et al. [13] determined the effi-
cacy of drugs by measuring the distance in the graph be-
tween drug target proteins and disease proteins (i.e. the
proteins coded for by the genes that are associated with
a disease). The underlying assumption was that a shorter
distance between drug targets and disease proteins was
associated with a higher likelihood of efficacy. Although
they described a coherent and plausible mechanism by
which the efficacy of drugs could be explained, the per-
formance of their method in determining the efficacy of
drugs was moderate, with an area under the ROC curve
of 66%.
Recent methods have included predicate information
in knowledge-graph analyses [14–16]. Alshahrani et al.
first transformed individual entities and predicates in
their knowledge graph to numeric vector representations
with the RDF2vec tool [14]. Machine learning was used
on these vectors to predict new relationships for different
pharmacological use cases. However, due to the complex-
ity of the transformation performed by the RDF2vec tool,
this method provides no insight into a possible functional
mechanism. Weissenborn et al. created a knowledge graph
based on a very large number of predicate types extracted
from the biomedical literature, to which they applied ma-
chine learning [15]. They exclusively focused on literature
and did not utilize the large amounts of knowledge con-
tained in databases. Himmelstein et al. extracted paths of
varying lengths between drugs and diseases from their
knowledge graph [16]. Only a limited number of predicate
types could be found in these paths; the majority of the
entity types in their knowledge graph could only be
connected to each other by a single predicate type. The
predicate and entity types in these paths were com-
bined to create so-called metapaths (e.g. “Compound–
binds–Gene–associates–Disease”). Machine learning was
used on all metapaths between a drug and a disease to clas-
sify whether it could be used as a treatment. Their decision
to only include a limited number of predicates in their know-
ledge graph may under-utilize the information available in
knowledge sources, which often describe multiple predicate
types between the same types of entities. None of the
methods mentioned above used provenance information.
Here, we investigate the added value of predicate and
provenance information for drug efficacy screening by
using them as features for a machine learning algorithm.
We extract the predicate and provenance information
from a comprehensive, commercially available know-
ledge graph, which contains knowledge from scientific
literature as well as from a large number of databases.
We compare our method with the state-of-the-art method
of Guney et al., which does not use predicate and proven-
ance information [13].
Methods
Knowledge graph
We used the Euretos Knowledge Platform (EKP), a com-
mercially available knowledge graph [18]. The EKP is a
generic platform, which contains information from 176
existing knowledge sources from a wide variety of do-
mains in the life sciences. Biomedical entities such as
proteins, drugs, or diseases are represented in the
knowledge graph as vertices, each of which has one or
more identifiers associated with it from external data-
bases. The predicates and provenance between a sub-
ject and an object form a set of triples that define the
edge between the vertices representing the subject and
object. A path between two vertices is defined as a se-
quence of triples, or possibly a single triple, connecting
the vertices.
Mappings between the entities in the different know-
ledge sources underlying the knowledge graph were
made by matching their identifiers. The predicates in the
knowledge sources were matched to a set of 203 predi-
cate types, which are based on the predicates defined in
the UMLS, extended with predicates from other know-
ledge sources [19]. If an exact match was not available,
the predicates were manually mapped. If there were no
explicit predicates in a database that was used as a
knowledge source, the predicates were derived from the
database schema.
To investigate the functional mechanisms behind the
efficacy of drugs, we worked on the human protein level,
similar to Guney et al. [13]. Knowledge graphs consisting
solely of protein-protein interactions have been exten-
sively used to investigate (interactions between) diseases,
although these analyses typically do not use predicate or
provenance information [20–22]. Sets of drug target pro-
teins (henceforth referred to as drug targets) were used
to represent one or more drugs, while sets of disease pro-
teins were used as representatives of one or more diseases.
A set consisted of one or more proteins. Apart from pro-
tein information, no information about the other entity
types available in the knowledge graph was used.
When extracting the paths between drug targets and
disease proteins from the EKP we distinguished three
scenarios, as shown in Fig. 1. In the first scenario, a disease
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protein is also a drug target. Sometimes, these proteins are
known to have a relationship with themselves, e.g. homodi-
merization, represented in Fig. 1a as a dotted line. In the
second scenario, shown in Fig. 1b, there is a direct relation-
ship between a drug target and a disease protein. In the
third scenario a drug target and disease protein do not
have a direct relationship, but there is an indirect relation-
ship between them that goes through an intermediate pro-
tein (Fig. 1c). To keep the graph comprehensible, we made
the choice to use paths with a maximum length of two, i.e.
paths with at most one intermediate protein, for indirect
relationships. Guney et al. previously showed that these
paths cover 90% of the relationships between drug targets
and disease proteins, and that using longer paths does not
improve performance [13].
Reference sets
To evaluate and benchmark the performance of our
method, we used the reference set created by Guney et
al. [13]. Furthermore, we created a second reference set
using a similar procedure as Guney et al. However,
whereas Guney combined related diseases into disease
classes that minimally have 20 disease proteins, the sec-
ond reference set includes any disease for which disease
proteins are known.
The Guney reference set
The reference set created by Guney et al. [13] consists of
402 “known” drug-disease combinations. Table 1 pro-
vides an overview of the characteristics of this reference
set. The reference set contains 238 drugs, each of which
is represented by a unique set of drug targets. The 78
diseases contained in the reference set are represented
by an equal number of disease protein sets, of which 74
sets are unique.
Disease proteins were obtained from the Online Men-
delian Inheritance in Man (OMIM) database and GWAS
studies, and drug targets were obtained from DrugBank.
The drug indications were obtained from the Medication
Indication – High Precision Subset (MEDI-HPS) [23],
which was further filtered for strong literature evidence
by using the Metab2MeSH tool [24]. Finally, Guney et al.
manually checked all drug labels to confirm that they were
used to treat the disease. A complimentary set of “unknown”
combinations was created by taking all possible drug-disease
combinations, excluding the 402 “known” combina-
tions. This “unknown” set consisted of drug-disease
combinations that are likely to be ineffective. In the
following, we shall refer to the “known” and “unknown”
combinations as positive and negative combinations,
respectively, to align with common terminology in the
machine learning field.
a
b
c
Fig. 1 The three included relationship scenarios. The three scenarios of relationships between drug targets and disease proteins are shown along
with examples which can be found in the knowledge graph. a Drug target (DT) and disease protein (DP) are the same protein. The protein may
have a relationship with itself (dotted line). b DT and DP have a direct relationship. c DT and DP have an indirect relationship through an
intermediate protein (IP). Indirect relationships consist of two steps (DTIP and IPDP)
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The Guney reference set only included a disease if at
least 20 disease proteins were associated with it. This
criterion biases the reference set towards well-charac-
terized diseases. Furthermore, diseases with fewer disease
proteins were rolled-up based on the MeSH hierarchy
until a MeSH entry with 20 or more disease proteins was
found. As a result, the reference set contains entries such
as “neoplasms”, “bone diseases”, “kidney diseases”, and
“autoimmune diseases”, which are better described as dis-
ease classes rather than individual diseases.
The EMC reference set
The second reference set, which we refer to as the EMC
(Erasmus Medical Centre) reference set, covers 708
drugs, represented by 314 unique sets of drug targets. Its
285 diseases are represented by 281 unique sets of dis-
ease proteins, the minimum set size of which is lowered
to 1. The resulting reference set consists of 1250 unique
combinations of drug target and disease protein sets
(Table 1).
Drug targets were obtained from the review by Santos
et al. [25], which is stated to describe a more compre-
hensive and consistent list of drug targets than DrugBank.
The disease proteins were obtained from DisGeNet, from
which we used the manually curated subset [26]. Drug in-
dications were obtained from MEDI, which extracts them
from the literature with an ensemble text-mining pipeline
[23]. We used the “high precision” subset (HPS) of MEDI,
as provided by the authors. Similar to the Guney reference
set, negative cases were created by taking all possible
combinations of the sets of drug targets and disease pro-
teins, excluding the “known” combinations.
Feature sets and machine learning
We used the three scenarios of drug target-disease pro-
tein combinations (see Fig. 1) as the basis for our feature
generation. For each scenario, a binary feature table was
created of all predicates and corresponding provenance
(Fig. 2):
1) Overlap, a binary feature which indicated whether
one or more disease proteins were also drug targets.
If a protein had a relationship with itself in the
knowledge graph (for example because it
homodimerizes), this information was also included
as binary features. However, such self-relationships
were not available for all overlapping proteins.
2) Direct relationships, filling in the binary table of the
predicates and provenance of all the direct
relationships between drug targets and disease
proteins.
3) Indirect relationships, split into two steps as shown
in Fig. 1c. For each step, a binary table of the
predicates and provenance was filled in.
To assess and quantify the value of predicate and prov-
enance information, we performed multiple experiments
with variations of the feature sets:
– A baseline was set by classifying drug target-disease
protein combinations without any predicate and
provenance information. To do so, three binary
co-occurrence features were created: “overlap”, “has_
direct_relationship”, and “has_indirect_relationship”.
These features indicate whether the paths between
the drug targets and disease proteins belong to one or
more of the three scenarios described earlier.
– Drug target-disease protein combinations were
classified using only the predicate features or only
the provenance features, thereby quantifying the
value of each.
– Drug target-disease protein combinations were
classified with both predicate and provenance
information, which constituted the complete
feature set.
– All the features from the overlapping drug targets
and disease proteins and the direct relationships
were removed. Removing these features allowed us
to quantify the dependence of our method on the
proximity between drug targets and disease proteins.
Random forests were trained to classify a combination
of drug targets and disease proteins as positive or
Table 1 Characteristics of the two reference sets
Characteristics Guney reference set EMC reference set
Source of drug-disease
indications
MEDI-HPS +Metab2MeSH
+manual curation
MEDI-HPS [23]
Drug target sets 238 314
Unique drug targets 384 539
Source of drug targets DrugBank Santos et al. [25]
Disease protein sets 78 281
Unique disease proteins 2726 3205
Minimum size of disease
protein set
20 1
Median size of disease
protein set
52 5
Maximum size of disease
protein set
606 273
Source of disease
proteins
OMIM + GWAS DisGeNet, curated
subset [26]
Number of positive
cases
402 1250
Number of negative
cases
18,162 86,984
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negative. We chose random forests because they have
shown excellent performance as compared to other classi-
fiers on a wide range of problems [27], and they can calcu-
late the importance of individual features. Classifications
were performed on all positive combinations and an
equally-sized sample of randomly selected negative combi-
nations. Classification performance was assessed by the
area under the ROC curve (AUC) of a 10-fold cross-
validation experiment [28]. We report the mean and stand-
ard deviation of the AUCs of 100 repeated cross-validation
experiments. For the classifications that were performed
on the complete feature sets we also report the area under
the precision and recall curve (AUPR) [29].
To compare our method with the proximity-based
method of Guney et al., we implemented their method
with the code provided on GitHub [30]. As an input, we
used the protein-protein interaction data extracted from
the EKP.
Feature extraction, machine learning, and evaluation
were performed in R [31] with the packages caret [32],
randomForest [33], pROC [34], and PRROC [35].
Results
Extracted paths
We extracted 1.58 million triples with proteins both as
subject and object from the EKP, involving a total of
15,124 proteins. Almost a third of these, 4899, were dis-
ease proteins for one or more diseases. From a total
number of 706 drug target proteins in the two reference
sets, there were 425 (60%) which were also disease pro-
teins. Drug targets and disease proteins were connected
by 267,032 direct paths, and almost 50 million indirect
(two-step) paths. In total, there were 1.45 million edges
between the proteins. The triples were taken from 25 dif-
ferent knowledge sources [see Additional file 1: Table S1],
and contained 45 different predicate types [Additional
file 1: Table S2]. A small percentage of the disease pro-
teins (3% for the Guney reference set and 1% for the EMC
reference set) were not used in the analyses because the
EKP did not contain a direct or two-step indirect path be-
tween the disease protein and a drug target. All drug tar-
gets were connected to a disease protein through a direct
or indirect path.
Fig. 2 Schematic overview of the feature extraction and classification process. For the sake of readability, this overview figure only shows the
process for predicates. The input set contains the combinations of drug targets (DT) and disease proteins (DP) that are to be classified. Step 1:
Extract paths. The paths between drug targets and disease proteins are extracted from the knowledge graph. Paths can be direct or indirect.
Indirect paths have one intermediate protein (IP) and are separated in two steps: DTIP (drug target – intermediate protein) and IPDP
(intermediate protein – disease protein). Step 2: Extract features. The feature set consists of all possible predicates and provenance, for each of the
three scenarios (cf. Fig. 1). Based on the extracted paths for a combination, the presence or absence of each feature is set. Step 3: Classify. Based on
the extracted features, the combinations are classified by a random forest classifier
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Classification results
The outcomes of all experiments are shown in Table 2,
which lists the mean AUC values and their standard devia-
tions for both reference sets. The baseline performance of
our reduced feature set, consisting of overlap and co-oc-
currence features, was 59.8% for the Guney reference set
and 64.9% for the EMC reference set. Both predicate fea-
tures and provenance features substantially improved per-
formance as compared to baseline. Using only predicate
features achieved a higher performance than provenance
features, performing almost equal to classifying with the
complete feature sets. The combination of predicate and
provenance features performed best, with an AUC of
78.1% for the Guney reference set, and 74.3% for the EMC
reference set. The mean and standard deviation of the
AUPR for these two sets was 80.3% (1.5%) and 76.5%
(0.9%), respectively. When only features from indirect re-
lationships were used, the mean AUC for both reference
sets decreased by 3.7 percentage points.
Application of Guney’s proximity metric to the paths
extracted from the EKP resulted in an AUC of 65.6% for
the Guney reference set, similar to the AUC of 66% that
was previously reported [13]. Classification of the EMC
reference set based on their proximity metric achieved
an AUC of 64.6%. Comparing our method with Guney’s
method, we see an improvement in AUC of 12.5 per-
centage points for the Guney reference set, and of 9.7
percentage points for the EMC reference set.
To ensure a valid comparison with the work of Guney
et al., we used a balanced training set with an equal
number of positive and negative cases. We assessed the
effect of varying the ratio of positive and negative
cases in the training set, and found that an increase in
the number of negative cases slightly improved per-
formance for the Guney reference set (up to AUC
80.8% for a 10:1 ratio) [see Additional file 2]. For the
EMC reference set, no performance improvement was
found.
Importance of predicates and provenance
To determine the importance of individual features, we
used the standard feature importance calculation func-
tion of the random forest algorithm. Figure 3 shows the
ranking of the 20 most important features for one of the
cross-validation experiments. This experiment was per-
formed on the EMC reference set, using the full feature
set. The overlap feature was most important, followed
by three provenance features from direct relationships.
The number of predicate features in the top-20 most im-
portant features was about the same as the number of
provenance features.
We also examined the importance of the individual
knowledge sources. For each source in turn, we removed
the features that could only be derived from that source
from our feature set and performed a 10-times repeated
10-fold cross validation. For most knowledge sources,
exclusion barely changed the AUC. For only two know-
ledge sources, exclusion resulted in a decrease in AUC
of more than one percentage point. These were the
protein-protein interaction subsets from SemMedDB,
whose exclusion caused a decrease of 1.2 percentage
point, and the Comparative Toxicogenomics Database
(CTD), whose exclusion caused a decrease of 2.8 per-
centage points.
Influence of number of drug targets on classification
performance
The number of drug target proteins per drug varies con-
siderably, ranging from 1 to 26 for the Guney reference
set (mean of 3.5, median of 2), and from 1 to 51 for the
EMC reference set (mean of 3.4, median of 2). To inves-
tigate whether classification performance was dependent
on the number of proteins targeted by a drug, we strati-
fied both reference sets into three subsets: combinations
with one drug target, with two drug targets, and with
more than two drug targets. We then calculated the per-
formance of each subset based on the cross-validation
results of all combinations. The performance of the indi-
vidual subsets within these experiments is shown in Table 3.
Performance decreased when only a single drug target was
known, while performance increased for drugs with more
than one drug target.
Error analysis
We analysed the errors of one cross-validation experiment
on the EMC reference set, which achieved an AUC of
Table 2 Performance results for different feature sets
Feature set AUC Guney reference set AUC EMC reference set
Overlap and co-occurrence features 59.8% (0.9%)* 64.9% (0.6%)
Overlap and predicate features 77.6% (1.6%) 73.1% (0.9%)
Overlap and provenance features 75.1% (1.7%) 71.3% (1.0%)
Overlap, predicate and provenance features (all relationships) 78.1% (1.7%) 74.3% (1.0%)
Predicate and provenance features (indirect relationships only) 74.4% (1.9%) 70.6% (1.0%)
Guney’s proximity metric 65.6% (1.4%) 64.6% (0.6%)
*Values indicate mean and standard deviation of the AUCs of 100 experiments
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73.8%. The random forest classifier assigned probabilities
to the combinations. In the following, we qualitatively
analyse misclassifications from the extremes of the distri-
bution of these probabilities.
Qualitative analysis of false negatives
We further examined the eight false-negative cases with
a probability of less than 0.1. Four cases were classified
as negative because the diseases involved had only a
single associated disease protein, and the EKP did not
contain direct or two-step indirect paths between the
disease protein and the drug targets.
We considered two of the four remaining cases to be
clear classification errors. According to the product label
of colchicine, it is a valid treatment for familial mediter-
ranean fever [36]. Similarly, treating gastric immobility
with the gastrokinetic agents tegaresod and cisapride is
described in the literature [37].
The other two false-negative classifications were less
straightforward. One of these described the use of steroids
such as prednisolone or hydrocortisone to treat otitis
media. While this appears to be a commonly accepted
treatment [38], its validity has recently been disputed [39].
Treating kidney stones with diuretics such as hydrochlo-
rothiazide and polythiazide functions by increasing renal
clearance, thereby excreting any substance aggregates be-
fore they become kidney stones [40]. This treatment does
not influence the mechanisms that cause the substance to
Fig. 3 The most important features for a cross-validation experiment. The top-20 most important features when trained on the complete feature
set are presented. The importance measures, calculated with the standard feature importance calculation function of the random forest
algorithm, have been normalized. The colours indicate whether it is a predicate, provenance, or overlap feature. While knowledge sources
such as SemMedDB contain information about relationships between many types of entities, we only used the protein-protein interaction
(PPI) subsets of these datasets
Table 3 Classification performance stratified by the number of proteins targeted by a drug
Number of targets per drug Guney reference set EMC reference set
Number of combinations AUC Number of combinations AUC
1 133 71.8% (2.9%)* 552 71.8% (1.4%)
2 125 78.5% (2.4%) 244 75.6% (1.5%)
> 2 144 82.4% (2.2%) 454 76.6% (1.5%)
All 402 78.1% (1.7%) 1250 74.3% (1.0%)
*Values indicate the mean and standard deviation of the AUCs for 100 experiments
Vlietstra et al. Journal of Biomedical Semantics  (2018) 9:23 Page 7 of 10
form, but instead prevents their build-up from reaching
problematic concentrations.
Qualitative analysis of false positives
We similarly investigated the 15 false-positive cases with
random forest probabilities larger than 0.9. Two cases
appeared to be incorrectly marked as negative in our ref-
erence set. Low levels of brain natriuretic peptide are
known to be associated with hypertension [41], and am-
phetamines such as dextroamphetamine and lisdexamfeta-
mine are an accepted treatment for narcolepsy [42, 43].
For six cases, efficacy has been investigated, but the
drug proved to be ineffective or no conclusion about its
efficacy could be drawn. For example, the vasopressin re-
ceptor antagonist tolvaptan appeared to be effective
against the X-linked subclass of nephrogenic diabetes insi-
pidus [44]. However, since this finding was published in
2006, the drug does not appear to have become an ac-
cepted treatment [45]. Dextromethorphan has more re-
cently been described as a potential treatment for bipolar
disorder, and is currently under investigation in a clinical
trial [46, 47]. However, at the time of writing no results
have been published. The 5HT-antagonist ondansetron
was tested as a treatment for Alzheimer’s disease, but
failed to improve cognitive performance [48].
Five other drugs appeared to be potential causes rather
than treatments of the disease. For example, the drug
label of sotalol mentions that it can cause asthma [49],
and the drug label of pentoxifylline mentions that it can
cause hypotension [50].
For two false-positive cases we could not find any rela-
tionship in the literature: the use of carboprost to treat
acidosis, and of thrombin inhibitors to treat rheumatoid
arthritis do not appear to have been investigated. While
some animal studies mention the use of thrombin inhib-
itors for research on rheumatoid arthritis, the use of
these drugs appears to be part of a laboratory procedure,
not an experimental treatment [51, 52].
Discussion
We used a biomedical knowledge graph to extract features
for the automated classification of efficacious relationships
between drug targets and disease proteins. We have
shown that the use of predicate and provenance informa-
tion that is available in the knowledge graph substantially
improves classification performance as compared to
not using this information. To our knowledge we are
the first to use provenance information in a computa-
tional analysis. We performed our analysis on an exist-
ing, commercially available knowledge graph, saving us
the considerable amount of time and effort required to
integrate the knowledge sources with each other.
Compared to our baseline performance, which was
only based on co-occurrence information, using either
predicate or provenance information substantially improved
the classification results. With both reference sets, using
only predicate information achieved a higher performance
than only using provenance information, while using both
performed best. In all experiments, use of predicate and
provenance information surpassed the performance of the
method against which we benchmarked, the state-of-
the-art work by Guney et al. [13]. Performance improved
for drugs with more than one drug target, or when 20 or
more disease proteins were known. Removal of the overlap
and direct relationship features, which included the four
most important ones, showed that our method can still be
used when only indirect paths are available. A lack of
proximity between drug targets and disease proteins
can therefore be compensated with predicate and proven-
ance information. Excluding the information from a single
knowledge source generally had a minor impact on the
performance of our method. The largest performance
decrease (2.8 percentage points in AUC) was noted for
the exclusion of the protein-protein interactions from
CTD. Using more negatives cases than positive cases in
the training set may slightly increase classification
performance.
We created the EMC reference set to analyse diseases
with less than 20 disease proteins. This both increased
the number of diseases that could be included, and allowed
its disease entries to be more specific than the disease clas-
ses included by Guney et al. However, our error analysis re-
vealed that the EMC reference set was not perfect, with
one of its positive cases likely to be outdated, while in an-
other positive case the drug mitigated the symptoms of the
disease rather than treating its underlying causes. The
negative cases in the reference set were created by ran-
domly combining the positive cases. While this is a com-
mon approach [13, 15, 53], it assumes that there are no
undiscovered or missing relationships. Our error analysis
showed this assumption to be incorrect, with at least two
of the negative cases having a therapeutic relationship in
reality. Overall, our work would benefit from a comprehen-
sive gold standard, which would ideally consist of positive
and negative cases that have been manually verified by
experts.
Expert knowledge could also be leveraged to prune the
proteins, predicates, and provenance found in the paths.
In this research, the paths that we extracted from the
knowledge graph were immediately used to create the
features. It is therefore possible that some erroneous
paths were included in the analyses.
The feature set could be expanded with other types of
information. Network topology features could be used,
e.g. the centrality of drug targets and disease proteins in
the graph, as previously used by Mitsopoulos et al. [54]
and Xu and Li [55], or the proximity metric of Guney et
al. [13]. Furthermore, other types of entities, such as
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physiological or molecular processes could be added to
the paths. Finally, more detailed analyses of the proven-
ance underlying triples could be used to create features.
In cases where references to journal articles are available
in the triples, these can be used to obtain the journal
name, author information, and publication date. The value
of this information has already been demonstrated by
Heinemann et al. [56], who used temporal publication
patterns of articles, as well as the number of times a
single author published about a drug target to predict
the failure of drugs in phase II/III trials.
Finally, we could apply our method to other tasks.
Combinations of drugs, e.g. those in the Drug Combin-
ation Database [57], could be analysed by combining sets
of drug targets. Similarly, comorbidity [58] or diseases
trajectories [59] could be analysed by combining sets of
disease proteins. Furthermore, we would like to investigate
whether our method can be used to identify drugs or drug
targets for rare diseases. Because rare diseases receive less
attention from the scientific community, their relevant
proteins may be more poorly characterized. In such cases
our cut-off of two steps might be insufficient, as it already
was for four (0.3%) of the positive cases in the EMC refer-
ence set, which would necessitate adding another step to
the extracted paths. Our method may also be suitable for
predicting side effects of drugs, which was a common
error in our analysis of the false-positive cases. For this
task, the relationships of drug targets with proteins that
induce side effects would be analysed, instead of their rela-
tionships with disease proteins [13].
Conclusions
We have demonstrated the added value of predicate and
provenance information for knowledge-graph analyses.
By achieving a state-of-the-art performance for drug ef-
ficacy screening, our work contributes to the computa-
tional analysis of the comprehensive body of biomedical
knowledge.
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